MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
Mol Pharm. 2019 Jul 11;:
Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
Mol Pharm. 2018 08 06;15(8):3383-3393
J Nucl Med. 2019 May 03;:
Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.
Mol Pharm. 2019 Feb 04;16(2):768-778
Tumor uptake and tumor/blood ratios for 89Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1.
Nucl Med Biol. 2018 Oct 16;67:43-51
CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice.
Haematologica. 2018 Jul 05;:
Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
Mol Pharm. 2018 Jan 30;:
Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with (111)In, (177)Lu or (90)Y incorporated into tissue implantable depots.
Phys Med Biol. 2017 Oct 27;62(22):8581-8599
(64)Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
Mol Pharm. 2017 Feb 06;14(2):492-501